# Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
Canonical URL: https://biopharmsignal.com/news/APVO/aptevo-therapeutics-reports-3q25-financial-results-and-provides-a-business-update
Ticker: APVO
Company: Aptevo Therapeutics
Source: Aptevo Therapeutics
Published: 2025-11-06 13:05 EST
Original Source URL: https://aptevotherapeutics.gcs-web.com
## Summary

89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors Both molecules leverage Aptevo's unique

## Article Body
89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors Both molecules leverage Aptevo's unique
## Recent Company News
- 2026-05-28 12:05 EST — [Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-appoints-mary-j-janatpour-ph-d-as-senior-vice-president-and-chief-scientific-officer) — Source: Aptevo Therapeutics
- 2026-05-27 12:05 EST — [Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing](https://biopharmsignal.com/news/APVO/aptevo-and-niowave-launch-strategic-collaboration-for-radiopharmaceutical-therapeutic-development-includes-strategic-equity-investment-by-niowave-at-closing) — Source: Aptevo Therapeutics
- 2026-05-13 12:05 EST — [Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection](https://biopharmsignal.com/news/APVO/aptevo-therapeutics-provides-a-1q26-business-update-rainier-on-track-for-2026-completion-and-phase-2-dose-selection) — Source: Aptevo Therapeutics
- 2026-05-06 12:05 EST — [Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection](https://biopharmsignal.com/news/APVO/aptevo-reports-87-clinical-benefit-and-81-remission-in-31-evaluable-frontline-aml-patients-through-cohort-5-substantially-outperforming-benchmark-rainier-on-track-for-2026-completion-and-phase-2-dose-selection) — Source: Aptevo Therapeutics
- 2026-03-26 12:05 EST — [Aptevo Provides State of the Business Report and 2025 Financial Results](https://biopharmsignal.com/news/APVO/aptevo-provides-state-of-the-business-report-and-2025-financial-results) — Source: Aptevo Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)